RxDoctor Payments Data

Keith Taylor, MD

Family Medicine · Newport News, VANPI 1356322333

Payments from drug & device makers

$7,313in general payments, 2019–2025

Across 431 payments — averaging $16.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$832
  • AstraZeneca$729
  • Lilly USA, LLC$580
  • Amgen$522
  • Pfizer$500
  • plus $3K from 43 others

What the payments were for

  • Food & beverage$7,290100%
  • Education$220%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,313 in reported general payments places this provider in the 90th percentile of 2,553 family medicine providers in Virginia.

See all family medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$189,014
Medicare patients
335
Services billed
4,160

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban65$53,299
JardianceEmpagliflozin44$50,066
Trelegy ElliptaFluticasone/Umeclidin/Vilanter38$45,545
OzempicSemaglutide28$32,668
OxycontinOxycodone Hcl12$32,265
JanuviaSitagliptin Phosphate30$24,898
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog15$20,282
MounjaroTirzepatide18$18,668
XareltoRivaroxaban20$15,999
Lantus SolostarInsulin Glargine,hum.Rec.Anlog68$14,504
SymbicortBudesonide/Formoterol Fumarate14$5,799
Oxycodone Hcl158$3,416
Atorvastatin Calcium343$3,156
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen89$2,832
Levemir FlexpenInsulin Detemir17$2,721

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$500$53,29965 claims
Boehringer IngelheimJardiance$324$50,06644 claims
GSKTrelegy Ellipta$387$45,54538 claims
Novo NordiskOzempic$832$32,66828 claims
MerckJanuvia$44$24,89830 claims
Lilly USA, LLCMounjaro$580$18,66818 claims
Johnson & JohnsonXarelto$100$15,99920 claims
AstraZenecaSymbicort$729$5,79914 claims
AbbVieSynthroid$1,295$2,17141 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,553 family medicine providers in Virginia.

Other family medicine in Newport News

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →